Proqr Therapeutics N.V. income statement

In fiscal 2025, Proqr Therapeutics N.V. reported revenue of $18.0m, down 12.1% on the year before, operating income of −$49.1m (a -273.1% margin) and net income of −$47.7m, or −$0.45 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Proqr Therapeutics N.V.: income statement, annual
Fiscal year	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Revenue	2	4	7	20	18
Research and development	50	54	27	39	51
Operating income	−68	−69	−34	−33	−49
Interest expense	1	1	1	1	1
Income before tax	−72	−68	−30	−30	−48
Income tax	0	0	−0	−0	0
Net income	−72	−68	−30	−30	−48
Diluted EPS	−$1.12	−$0.95	−$0.38	−$0.35	−$0.45
Diluted shares (average)	64m	72m	81m	86m	105m
EBITDA	−65	−66	−32	−30	−46

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: CTMX vs PRQR CELU vs PRQR PRQR vs SCYX KROS vs PRQR

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Proqr Therapeutics N.V.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Proqr Therapeutics N.V.